Locust Walk Insights
LOCUST WALK INSIGHTS
Q1 2018 Trends in Biopharma Transactions Report
Locust Walk is a global transaction firm serving biopharma and medtech companies in the US, Europe, and Asia. Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Q1 2018 Trends in...
Q1 2018 Trends in Medtech Transactions Report
Locust Walk is a global transaction firm serving biopharma and medtech companies in the US, Europe, and Asia. Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Q1 2018 Trends in...
Let’s get digital, digital…
Often entrepreneurs are describing their new company as a digital health start up, but what exactly is digital health? Some incorrectly think it is anything medical with a website or connected to an iPad. In his book, The Fourth Wave, Paul Sonnier describes it as...
Indication Selection for a Platform Company: The Faustian Dilemma
At Locust Walk, we are often tasked with addressing complex strategic business issues for our biopharma clients. Perhaps one of the most common dilemmas is how best to optimize a given company’s clinical development strategy to maximize value. Specifically, many...
Explain Yourself! Avoiding Common Communications Pitfalls During Term Sheet Negotiations
Term sheet negotiations are rarely easy, and there are multiple ways negotiations can break down before a deal is reached. Like many things in the biopharma industry, a big success factor in successful term sheet negotiations is effective communication. Below are some...
Japan & China: So close yet so different
Having lived in Japan for more than 20 years, I have admittedly become perhaps a little too accustomed to the Japanese lifestyle. This is probably why after a few days in the hustle and bustle of Shanghai, I find myself looking forward to returning to the peace and...
Late-Stage Biopharma IPOs and the Commercialization Partnership – Predictor of Success?
Emerging biopharma companies with promising lead candidates in late-stage trials are often faced with a fundamental decision: go-it-alone (self-commercialize) or secure a strategic partner to support development and commercialization. It is a classic strategic choice...
Maximizing Your JP Morgan Healthcare Conference
The JP Morgan Healthcare Conference, or “JPM”, is the healthcare conference of the year. Companies from all over the world convene in San Francisco to setup meetings with investors, prospective partners, service providers, etc. and lay the groundwork for much of the...
We’re All Heart: Best in Show at TCT
It is that time of year again when the interventional cardiology and vascular communities reflect on the recent Transcatheter Cardiovascular Therapeutics (TCT) meeting which took place in Denver and finished late last week. We take pause to remember that TCT is one...
Finding the invisible, how to meet Family Offices
Besides calling the Ghostbusters, how does one catch a ghost? That is the question asked by most life science companies trying to raise capital from family offices, which we define as a non-institutional investor capable of investing $1M or more into an individual...
Navigating the MedTech Fundraising Environment
For many years, the fundraising environment for MedTech companies has been exceedingly difficult. Venture firms that were historically active in MedTech shifted their investment allocations to other areas of life sciences and capital became constrained. New entrants...
Biotalk, Episode 5, Fred Chereau, LogicBio
In this episode of Biotalk, Josh Hamermesh, VP of Locust Walk, spoke to Fred Chereau, CEO of LogicBio, an innovative early-stage gene therapy company that recently completed a $50M financing. During the conversation, Josh and Fred discussed career paths, industry...
Q3 2017 Trends in Life Sciences Finance
Each quarter Locust Walk experts compile key statistics and trends on strategic transactions and financings. Our Q3 report uses the latest data to analyze current trends in the life science deal landscape. In this report you can find an overview and analysis of:...
Demystifying the Venture Capital Term Sheet
Raising capital for an emerging biotech company is rarely easy. Tremendous time and effort goes into crafting the perfect story, determining the amount of capital you need to raise and what that money will be used for and reaching out to investors. It can be a long...
When to use a structured deal process?
Though often overlooked or made by default, decisions about the structure and timing of a competitive deal process can have a significant impact on the ultimate value realized by the sell-side company. There are many important decisions that must be made in the...